These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9099167)

  • 21. Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease.
    Goa KL; Barradell LB; McTavish D
    Pharmacoeconomics; 1997 Jan; 11(1):89-110. PubMed ID: 10172918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial.
    Jönsson B; Cook JR; Pedersen TR
    Diabetologia; 1999 Nov; 42(11):1293-301. PubMed ID: 10550412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.
    Grover SA; Coupal L; Paquet S; Zowall H
    Arch Intern Med; 1999 Mar; 159(6):593-600. PubMed ID: 10090116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S).
    Jönsson B; Johannesson M; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
    Eur Heart J; 1996 Jul; 17(7):1001-7. PubMed ID: 8809516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic impact of HIV infection and coronary heart disease in immigrants to Canada.
    Zowall H; Coupal L; Fraser RD; Gilmore N; Deutsch A; Grover SA
    CMAJ; 1992 Oct; 147(8):1163-72. PubMed ID: 1393930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Difficulties and limits in the evaluation of the cost of coronary disease in France].
    Clémenty J; Delpech MC; Mazeau C; Stingre P; Bricaud H
    Arch Mal Coeur Vaiss; 1983 Feb; 76 Spec No():55-67. PubMed ID: 6407450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost of allogeneic and autologous blood transfusion in Canada. Canadian Cost of Transfusion Study Group.
    Tretiak R; Laupacis A; Rivière M; McKerracher K; Souêtre E
    CMAJ; 1996 May; 154(10):1501-8. PubMed ID: 8625000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Real results of The Scandinavian Simvastatin Survival Study (4S)].
    Ostergaard Kristensen B
    Ugeskr Laeger; 1995 Apr; 157(15):2164-5. PubMed ID: 7652960
    [No Abstract]   [Full Text] [Related]  

  • 29. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study.
    Pedersen TR; Kjekshus J; Berg K; Olsson AG; Wilhelmsen L; Wedel H; Pyörälä K; Miettinen T; Haghfelt T; Faergeman O; Thorgeirsson G; Jönsson B; Schwartz JS
    Circulation; 1996 May; 93(10):1796-802. PubMed ID: 8635258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The Scandinavian Simvastatin Survival Study (4S)].
    Gram JB
    Ugeskr Laeger; 1995 Apr; 157(14):2020-1. PubMed ID: 7740647
    [No Abstract]   [Full Text] [Related]  

  • 31. [Economic analysis of secondary prevention of coronary heart disease with simvastatin (Zocor) in Germany].
    Obermann K; Mattias Graf ; Schulenburg JM; Mautner GC
    Med Klin (Munich); 1997 Nov; 92(11):686-94. PubMed ID: 9480401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Statin prevents coronary disease. The 4S study changes the therapeutic practice].
    Olsson AG
    Lakartidningen; 1995 Mar; 92(9):838, 843-4. PubMed ID: 7885109
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in The Netherlands.
    Martens LL; Rutten FF; Erkelens DW; Ascoop CA
    Am J Cardiol; 1990 Mar; 65(12):27F-32F. PubMed ID: 2107736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The 4S study and its pharmacoeconomic implications.
    Reckless JP
    Pharmacoeconomics; 1996 Feb; 9(2):101-5. PubMed ID: 10172696
    [No Abstract]   [Full Text] [Related]  

  • 35. Benefits of pharmaceutical innovation: the case of simvastatin in Canada.
    Thanh NX; Chuck AW; Ohinmaa A; Jacobs P
    Int J Technol Assess Health Care; 2012 Oct; 28(4):390-7. PubMed ID: 22989373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.
    Chrisp P; Lewis NJ; Milne RJ
    Pharmacoeconomics; 1992 Feb; 1(2):124-45. PubMed ID: 10146941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The 4S study is convincing--without explanation].
    Wennmalm A
    Lakartidningen; 1995 Mar; 92(9):844-6. PubMed ID: 7885110
    [No Abstract]   [Full Text] [Related]  

  • 38. Simvastatin after orthotopic heart transplantation. Costs and consequences.
    Krobot KJ; Wenke K; Reichart B
    Pharmacoeconomics; 1999 Mar; 15(3):279-89. PubMed ID: 10537435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of simvastatin versus cholestyramine: results for Sweden.
    Hjalte K; Lindgren B; Persson U
    Pharmacoeconomics; 1992 Mar; 1(3):213-6. PubMed ID: 10147032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group.
    Gotto AM; Boccuzzi SJ; Cook JR; Alexander CM; Roehm JB; Meyer GS; Clearfield M; Weis S; Whitney E
    Am J Cardiol; 2000 Dec; 86(11):1176-81. PubMed ID: 11090787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.